retatrutide trial safety FDA Approval Status 2026: Everything We Know So Far Retatrutide vs. Tirzepatide: A Network

The first randomised controlled trial of semaglutide for alcohol use disorder, published in JAMA Psychiatry in 2025, found that people taking low doses had fewer heavy drinking days, fewer cravings, and reduced alcohol intake compared to placebo

For weeks 912: Move to 2.5 mg (0.17 mL or 17 units) up until 3 mg for maintenance toward weight loss goals

Medication alone rarely addresses the underlying relationship patients have with food, control, distress, or self-image

Here we talk about GLP-1 weight loss for women in perimenopause, as well as talk through GLP-1 side effects in women and microdosing GLP-1 benefits.

Discover what happens if you miss a dose of tirzepatide and how to handle it safely